Lestronette

Ethinylestradiol and Levonorgestrel, the active ingredients in Lestronette, are a combined oral contraceptive presented as an oral tablet for oral use. This fixed‑dose combination provides estrogen and progestin activity to reliably prevent ovulation, modify cervical mucus, and stabilize the endometrium, thereby offering effective contraception and helping to regulate menstrual bleeding patterns in women of reproductive age.

GNH USA supplies Lestronette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Lestronette, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑gonadal axis to prevent pregnancy and manage menstrual disorders. - Contraception: provides reliable prevention of pregnancy by inhibiting ovulation. - Menstrual cycle regulation: helps establish regular, predictable bleeding patterns. - Ovulation suppression: reduces luteinizing hormone and follicle‑stimulating hormone release to stop egg release. - Endometrial stabilization: maintains a consistent endometrial lining, reducing irregular spotting. - Cervical mucus thickening: alters cervical secretions to impede sperm penetration.

Lestronette may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset, often improves with continued use. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Weight gain: slight increase in body weight. - Mood changes: irritability or mild depressive symptoms. - Spotting or breakthrough bleeding: irregular light bleeding between periods.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in legs or lungs. - Pulmonary embolism: blockage of pulmonary artery. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Lestronette, clinicians should evaluate several safety considerations. - Contraindications: avoid in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease. - Smoking: contraindicated for smokers over 35 years due to increased cardiovascular risk. - Cardiovascular risk: assess hypertension, diabetes, or hyperlipidaemia before use. - Drug interactions: review concomitant medications that may affect hormone metabolism. - Pregnancy and lactation: discontinue if pregnancy is confirmed; not recommended during breastfeeding. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Lestronette can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Combined hormonal contraceptives with other estrogen‑containing products: may increase risk of thrombosis. - Anticoagulants (e.g., warfarin): can reduce anticoagulant effect, requiring monitoring. - Hepatic enzyme inducers (e.g., rifampicin, carbamazepine): markedly decrease contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin, phenobarbital): may lower hormone levels, reducing efficacy. - Antiretrovirals (e.g., efavirenz): can reduce contraceptive effectiveness. - St. John’s wort: may decrease plasma concentrations of the hormones. - Antibiotics (e.g., tetracycline): generally minimal effect but monitor for breakthrough bleeding.